- January 9, 2017
- Posted by: admin
- Categories: Market Research NPP, Optio company news
January 2017 – Optio engages with industry thought leaders to obtain insights supporting the valuation of two prospective rare disease compounds. This valuation project created supporting research as a precursor to our client obtaining initial investment for compound acquisition or in-licensing.